Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)


Moehler M. H. , Dvorkin M., Ozguroglu M. , Ryu M., Muntean A. S. , Lonardi S., ...Daha Fazla

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Kostarika, 23 - 25 Ocak 2020, cilt.38 identifier

  • Cilt numarası: 38
  • Basıldığı Şehir: San-Francisco
  • Basıldığı Ülke: Kostarika